Scholars Central

Conference abstractPublished 29 Feb 2016

Evaluation of immune response to intravenously administered human cord blood stem cells in the treatment of symptoms related to chronic inflammation

Authors: Brian M Mehling, Louis Quartararo, Marine Manvelyan, Paul Wang, Dong-Cheng Wu

Blue Horizon International LLC, USA; Wuhan University, China; Wuhan Hongqiao Brain Hospital, China

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

BHI Therapeutic Sciences, LLC is a healthcare research and consulting company dedicated to the development of stem cell therapies. Our scientific and medical teams are focused on IRB approved protocols, designed to measure the safety and efficacy of intravenous, intra-articular and intrathecal stem cell treatments. The purpose of our study is primarily to monitor the immune response in order to validate the safety of intravenous infusion of human umbilical cord blood derived MSCs (UC-MSCs) and secondly to evaluate effects on biomarkers associated with chronic inflammation. Twenty patients were treated for conditions associated with chronic inflammation and for the purpose of anti-aging. They have been given one intravenous infusion of UC-MSCs. Our study of blood test markers of 20 patients with chronic inflammation before and within three months after MSCs treatment demonstrates that there is no significant changes and MSCs treatment was safe for the patients. Analysis of different indicators of chronic inflammation and aging included in initial, 24 hours, two weeks and three months protocols showed that stem cell treatment was safe for the patients; there were no adverse reactions. Moreover data from follow up protocols demonstrates significant improvement in energy level, hair, nails growth and skin conditions. Intravenously administered UC-MSCs were safe and effective in the improvement of symptoms related to chronic inflammation. Further close monitoring and inclusion of more patients are necessary to fully characterize the advantages of UC-MSCs application in treatment of symptoms related to chronic inflammation.

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Cell Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cell Science & Therapy
  • SubjectBiology
  • BylineArticles whose byline prints “Brian M Mehling”
  • BylineArticles whose byline prints “Louis Quartararo”
  • BylineArticles whose byline prints “Marine Manvelyan”
  • BylineArticles whose byline prints “Paul Wang”
  • BylineArticles whose byline prints “Dong-Cheng Wu”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels